PierreLarcher

Associate

Paris + 33.1.56.59.39.29

Connect:

Share

Pierre Larcher practices in the area of general corporate and securities law, focusing on capital markets and public M&A deals. He advises companies and financial institutions on a wide array of capital markets transactions including equity and debt offerings and initial public offerings (IPOs).

Prior to joining Jones Day in 2018, Pierre worked as an intern for a Magic Circle law firm and in the securities law and corporate governance department of a leading French pharmaceutical and health care group.

Experience

  • Bryan, Garnier & Co Limited and ODDO BHF SCA complete €29.8 million capital increase of MedinCell S.A.Jones Day represented Bryan, Garnier & Co Limited (acting via Bryan Garnier Securities SAS) and ODDO BHF SCA, as joint global coordinators and joint bookrunners, in connection with the €29.8 million capital increase of MedinCell S.A., a clinical stage pharmaceutical company.
  • Bank Degroof Petercam SA/NV and Invest Securities complete €18.6 million private placement of shares by OSE Immunotherapeutics S.A.Jones Day represented Bank Degroof Petercam SA/NV and Invest Securities SA in connection with the €18.6 million private placement of shares by OSE Immunotherapeutics S.A., a French integrated biotechnology company developing innovative immunotherapies, directly or through partnerships, for immune activation and regulation in immuno-oncology and autoimmune diseases.
  • Bryan, Garnier & Co Limited and Chardan Capital Markets complete €25 million private placement of shares by GenSight Biologics S.A.Jones Day represented Bryan, Garnier & Co Limited and Chardan Capital Markets, LLC in connection with the €25 million private placement of shares by GenSight Biologics S.A., a French clinical-stage gene therapy company in the area of severe retinal neurodegenerative diseases.
  • Kartesia Management restructures and refinances ORAPI and its holding company La Financière MG3FJones Day advised Kartesia Management SA in connection with the conciliation procedure, restructuring, and refinancing of ORAPI and the refinancing and restructuring of its holding company La Financière MG3F through multiple equity and debt instruments.
  • AXA Home Loan SFH issues €500 million of Soft Bullet Covered Bonds under its 2020 updated €10 billion Covered Bonds issuance programmeJones Day represented Natixis, as arranger and permanent dealer, and AXA Home Loan SFH, as issuer, in connection with the update of the €10 billion EMTN programme for the issuance of Covered Bonds (obligations de financement de l’habitat) of AXA Home Loan SFH signed on June 15, 2020.
  • Oddo BHF SCA and Bryan, Garnier & Co Limited complete €15.6 million share capital increase of MedinCell S.A.Jones Day advised Oddo BHF SCA and Bryan, Garnier & Co Limited, as placement agents, in connection with the €15.6 million share capital increase of MedinCell S.A., a clinical stage pharmaceutical company.
  • Crédit Agricole Home Loan SFH issues €2 billion Soft Bullet Covered BondsJones Day represented Crédit Agricole Home Loan SFH, as issuer, in connection with its issuance of €2 billion 0.125% Soft Bullet Covered Bonds.
  • Joh. Berenberg, Gossler & Co. KG; Gilbert Dupont; and Louis Capital Markets complete IPO of Ordinary Shares of Nacon S.A. on regulated market of Euronext in ParisJones Day advised Joh. Berenberg, Gossler & Co. KG; Gilbert Dupont; and Louis Capital Markets UK LLP in connection with the €100 million initial public offering of Ordinary Shares of Nacon S.A., a French company specialized in the development of video games and gaming accessories, on the regulated market of Euronext in Paris.
  • Bombardier to sell transportation business to Alstom for €6.2 billionJones Day is serving as antitrust and French corporate counsel in the €6.2 billion sale of Bombardier Inc.'s transportation business to Alstom S.A.
  • Selectirente completes €217 million capital increaseJones Day represented Selectirente S.A. in connection with the €217 million share capital increase without preferential subscription rights but priority subscription period granted to the existing shareholders.
  • Société Générale sold SKB Banka (Slovenia) and its subsidiaries to OTP BankJones Day advised Société Générale in the sale to OTP Bank Nyrt. of its shareholding in the share capital of its subsidiary specializing in retail banking, SKB Banka d.d. Ljubljana (Slovenia), and of its subsidiaries SKB Leasing d.o.o. and SKB Leasing Select d.o.o.
  • Société Générale sold Ohridska Banka (Macedonia) to Steiermärkische Bank und Sparkassen AGJones Day advised Société Générale in the sale of majority stake in Ohridska Banka AD Skopje (Republic of North Macedonia) to Steiermärkische Bank und Sparkassen AG.
  • UCB S.A. completes €3 billion EMTN ProgrammeJones Day advised UCB S.A. in connection with the set-up of their €3 billion EMTN Programme for issuance of notes.
  • Gilbert Dupont; Joh. Berenberg, Gossler & Co. KG; and Portzamparc complete IPO of BoostheatJones Day advised Gilbert Dupont; Joh. Berenberg, Gossler & Co. KG; and Portzamparc, as joint global coordinators, joint lead managers, and joint bookrunners, in connection with the initial public offering of Boostheat SA, a designer, developer, and producer of technologically advanced, energy efficient, and sustainable heating solutions, on the regulated market of Euronext in Paris.
  • Trafigura acquires majority stake in Nyrstar operating businessJones Day advised Trafigura Group Pte. Ltd. (“Trafigura”), a market leader in the global commodities industry, in connection with its acquisition of a majority stake in the operating business of Nyrstar, a multi-billion dollar global metals business.
  • Société Générale sells its majority stake in Mobiasbanca Societe Generale (Moldova) to OTP BankJones Day advised Société Générale in the sale of its majority stake in Mobiasbanca Societe Generale (Moldova) to OTP Bank Nyrt, the leading Hungarian bank.
  • Société Générale sells Societe Generale Montenegro to OTP BankJones Day advised Société Générale in the sale of Societe Generale Montenegro to OTP Bank.
  • Voltalia completes €376 million capital increase with shareholders’ preferential subscription rightsJones Day represented Voltalia S.A. in connection with its €376 million offering by way of preferential subscription rights allocated to Voltalia's existing shareholders in a public offering in France and internationally in private placements to institutional investors.
  • Syndicate of leading banks complete €715 million share capital increase by Tikehau CapitalJones Day advised Berenberg, Credit Suisse, Natixis, BNP Paribas, Crédit Agricole Corporate and Investment Bank, and Société Générale, as global coordinators, joint lead managers and joint bookrunners, and Citigroup and RBC Capital Markets, as joint lead managers and joint bookrunners, in connection with the €715 million share capital increase without shareholders' preferential subscription rights and with a priority subscription period for existing shareholders by Tikehau Capital, an asset management and investment group.
  • SVB Leerink, Barclays, Bryan Garnier, and Natixis underwrite $155.4 million Nasdaq IPO by GenfitJones Day acted as French counsel to the underwriters, led by SVB Leerink and Barclays, as global coordinators, and Bryan Garnier and Natixis, as European bookrunners, in connection with the initial public offering of Genfit S.A., a French Euronext Paris-listed biotechnology company on Nasdaq for a total aggregate amount of $155.4 million, after full exercise of the over-allotment option.
    • View All
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.